SEC Form 4 · accession 0001209191-17-047590
ACHIEVE LIFE SCIENCES, INC. · ACHV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
H Stewart Parker
Director
Period of report
Aug 1, 2017
Accepted (ET)
Aug 3, 2017 · 8:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000949858
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 1,136 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | $4.57 | Aug 1, 2017 | A | 11,000 | A | Aug 1, 2018 | Aug 1, 2027 | Common Stock | 11,000 | 11,000 | D |
| Stock Option (right to buy)F1,F2 | $156.20 | holding | — | — | — | — | Jun 8, 2020 | Common Stock | 67 | 67 | D |
| Stock Option (right to buy)F1,F2 | $196.02 | holding | — | — | — | — | May 26, 2021 | Common Stock | 318 | 318 | D |
| Stock Option (right to buy)F1,F2 | $138.16 | holding | — | — | — | — | May 31, 2022 | Common Stock | 363 | 363 | D |
| Stock Option (right to buy)F1,F2 | $118.03 | holding | — | — | — | — | May 24, 2023 | Common Stock | 454 | 454 | D |
| Stock Option (right to buy)F1,F2 | $39.82 | holding | — | — | — | — | Jun 5, 2024 | Common Stock | 454 | 454 | D |
| Stock Option (right to buy)F1,F2 | $20.79 | holding | — | — | — | — | May 21, 2025 | Common Stock | 454 | 454 | D |
| Stock Option (right to buy)F1,F2 | $11.00 | holding | — | — | — | — | May 26, 2026 | Common Stock | 2,045 | 2,045 | D |
Explanation of responses
- F1Reflects the 11-for-1 reverse stock split effected on August 1, 2017 immediately following the merger between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc.
- F2The options are fully vested and exercisable.